
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
An advisory board to the Food and Drug Administration was unanimous in recommending the approval of Raptiva, a psoriasis drug manufactured by Genentech.